Changing of the guard at Alliance

Share this article:
Next month's meeting of the Alliance for CME (ACME) will be the last for Bruce Bellande, PhD, as executive director.

A decision on his replacement is set to be made at the meeting. Bellande held the paid post for more than a decade.

ACME—the CME profession's largest member group—will see several officers and elected directors begin their terms next month.

Among those taking or returning to office are board members Greg Paulos, Winnie Brown, Damon Marquis and Mark Schaffer. Last year the board elected Paulos as secretary-treasurer-elect and Sue Ann Capizzi, MBA, as president-elect.  

Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...